Accounting Estimates Based on Assumptions Regarding Containment of the Infectious Disease
First written in FY2020. 4 of 7 entries say "Restated". Latest entry: FY2023-Q1.
The whole theme swung hardest in 2026: 5 of 22 companies on the "Worse" side.
- FY2023-Q1RestatedAnnual report
「There were no material changes to the assumptions, including the expected timing of the end of the COVID-19 pandemic, stated under “Significant Accounting Estimates” in the securities report for the previous consolidated fiscal year.」
It has been reconfirmed that there have been no material changes to the assumptions underlying accounting estimates concerning the timing of the infectious disease's containment and related matters. - FY2022-Q1RestatedAnnual report
「There were no material changes to the assumptions, including the expected timing of the end of the COVID-19 pandemic, stated under “Significant Accounting Estimates” in the securities report for the previous consolidated fiscal year.」
It has been reconfirmed that there have been no material changes to the assumptions underlying accounting estimates concerning the timing of the infectious disease's containment and related matters. - FY2021ReframedAnnual report
「We have made the relevant accounting estimates based on the assumption that the impact will continue throughout the fiscal year ending October 2022.」
The assumption that the impact of the infectious disease will continue through the fiscal year ending October 2022 has been reflected in accounting estimates, including impairment losses and deferred tax assets. - FY2021-Q3RestatedAnnual report
「Although our basic approach remains unchanged as vaccination progresses worldwide, we changed our assumption for the United Kingdom because the impact of the infection has been severe there, and recovery is expected to take longer than projected at the end of the previous consolidated fiscal year. There have been no material changes to the certain assumptions stated under Additional Information in the second-quarter report for the current consolidated fiscal year.」
It states that there have been no material changes from the second-quarter report to the accounting estimates concerning the timing of the infectious disease's containment and the normalisation of economic conditions. The assumption that the UK's recovery would take longer has also been maintained. - FY2021-Q2Downward revision to assumptions for the UK's recoveryAnnual report
「Although our basic approach remains unchanged as vaccination progresses worldwide, we changed our assumption for the United Kingdom because the impact of the infection has been severe there, and recovery is expected to take longer than projected at the end of the previous consolidated fiscal year.」
Regarding accounting estimates related to the infectious disease, the overall basic approach remains unchanged, but the assumption regarding the timing of the recovery in the UK has been changed. - FY2021-Q1RestatedAnnual report
「There have been no material changes to the assumptions, including the timing of the containment of COVID-19, stated under Additional Information in the annual securities report for the previous consolidated fiscal year.」
The accounting estimate assumptions from the previous fiscal year regarding the timing of the infectious disease subsiding and the economic environment normalizing continue to be applied. - FY2020First statedAnnual report
「For the fiscal year ending October 2021, our Group made accounting estimates, including judgments regarding the recoverability of deferred tax assets and impairment loss recognition, and reflected them in our accounting treatment based on the assumption that, although the business would be affected by the infectious disease to some extent, the disease would subside and the economic environment would begin to normalize, with a degree of normalization from the fiscal year ending October 2022 onward.」
The company has reflected in its accounting estimates, including the recoverability of deferred tax assets and impairment assessments, the assumption that the infectious disease would subside in the fiscal year ending October 2021 and that the economic environment would normalize to some extent from the fiscal year ending October 2022 onward.